Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3039% below fair value
$10.29−0.02 (-0.19%)
Close on Nov 19, 2026Market cap $629.10MP/E –Yield –
Janux Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Janux Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$41.93M. For fiscal 2025 it was -$83.28M. The highest annual figure on record is -$4.37M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$83.28M | – |
| FY2024 | Dec 31, 2024 | -$44.17M | – |
| FY2023 | Dec 31, 2023 | -$52.43M | – |
| FY2022 | Dec 31, 2022 | -$49.37M | – |
| FY2021 | Dec 31, 2021 | -$18.46M | – |
| FY2020 | Dec 31, 2020 | -$4.37M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.28M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.93M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.49M | -330.9% |
| Q4 FY2021 | Dec 31, 2021 | -$11.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.28M | – |
| Q1 FY2021 | Mar 31, 2021 | $5.41M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.08M | – |
See a number that looks wrong?